Johnson & Johnson
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson Orthopaedics Franchise by Quarter
Orthopaedics Franchise — Worldwide reported growth YoY (%) (%)
Johnson & Johnson Orthopaedics Franchise: 3.2% in Q3 2026, down 0.6 pts from a year earlier.
Latest, Q3 2026
3.2%
Period ended Sep 30, 2026
Change on a year earlier
-0.6 pts
3.8% in Q3 2025
History
36 quarters
Since Q4 2017
Sources
36
Documents cited below
Where the Q3 2026 figure comes from
“|| WW | 2,345 | 2,274 | 3.2 | 3.4 | (0.2)”
Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Johnson & Johnson Orthopaedics Franchise (%), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/mt-orthopaedics-rep-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.